^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AVX901

i
Other names: DUKE-002-VRP, VRP HER2 ECDTM, HUHER2-ECD+TM, HER2 VRP, HER2 ECDTM VRP, AVX901, AVX 901, VRP-HER2, VRP-HER2 ECDTM
Associations
Company:
AlphaVax
Drug class:
Immunostimulant
Related drugs:
Associations
over1year
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov)
P2, N=9, Active, not recruiting, Herbert Lyerly | Recruiting --> Active, not recruiting | N=39 --> 9
Enrollment closed • Enrollment change • Metastases
|
Keytruda (pembrolizumab) • AVX901
over3years
Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. (PubMed, Endocr Metab Immune Disord Drug Targets)
Although, commonly used treatments like trastuzumab/pertuzumab for human epidermal growth factor receptor 2 (Her2) positive and hormone therapy for estrogen receptor (ER) positive and/or progesterone receptor (PR) positive BC are specific but triple negative breast cancer (TNBC) cases remain a great challenge for treatment measures. Immune checkpoint inhibitors (anti-PD-1/ anti-CTLA-4) and anti-cancer vaccines (NeuVax, Muc-1, AVX901, INO-1400 and CEA), either alone or in combination with other therapies have created new paradigm in therapeutic world. In this review, we highlighted the current immunotherapeutic aspects and their ongoing trials towards the better treatment regimen for BC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MUC1 (Mucin 1)
|
ER positive • EGFR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • AVX901 • INO-1400 • NeuVax (nelipepimut-S)